Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
NCT ID: NCT02012127
Last Updated: 2019-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
648 participants
OBSERVATIONAL
2013-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Treatment and Natural History of Acromegaly
NCT00001981
Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients
NCT04860037
Treatment Patterns and Treatment Outcomes for Acromegaly
NCT03043586
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
NCT00500227
Acromegaly: Patient And Physician Perspectives
NCT03613623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acromegalic patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with acromegaly, diagnosed for less than 5 years
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Sud
Amiens, , France
CHU Besançon Hôpital Jean Minjoz
Besançon, , France
Hôpital la Cavale Blanche
Brest, , France
Chu Cote de Nacre
Caen, , France
Hôpital Henri Mondor
Créteil, , France
Chu de Grenoble Hôpital Albert Michallon
Grenoble, , France
Hôpital Claude Huriez
Lille, , France
Hôpital le Cluzeau
Limoges, , France
Hôpital Neuro-cardiologique
Lyon, , France
Hôpital de la Timone
Marseille, , France
Hôpital Lepeyronie
Montpellier, , France
Hôpitaux de Brabois
Nancy, , France
CHR Orléans - Hôpital la Source
Orléans, , France
CH de Bicetre
Paris, , France
CH Pitie Salpetreire
Paris, , France
Hôpital Lariboisiere
Paris, , France
Hôpital Haut Leveque
Pessac, , France
CHU Reims - Hôpital Robert Debre
Reims, , France
Hôpital Sud Anne de Bretagne
Rennes, , France
CHU Rouen - Hôpital de Bois Guillaume
Rouen, , France
Hôptital Nord
Saint-Etienne, , France
Hôpital Civil
Strasbourg, , France
Hôpital de Hautepierre
Strasbourg, , France
Hôpital Larrey
Toulouse, , France
CHU Bretonneau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B, Renoult PP, Houchard A, Elaraki F, Chanson P. Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study. Endocrine. 2019 Jan;63(1):120-129. doi: 10.1007/s12020-018-1764-4. Epub 2018 Sep 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-54-52030-266
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.